Laure-Anne Van Bellinghen

Statistics

Publications

Citations

209

H-Index

Active since

2014

Affiliations

GlaxoSmithKline (Belgium)(Current)

Imelda Hospital

GlaxoSmithKline (United States)

Laure-Anne Van Bellinghen is an author at GlaxoSmithKline (Belgium) specializing in general epidemiology, pediatrics, and infectious disease epidemiology.

ORCID

Top concepts

MedicinePediatricsVaccinationVaccinologyEpidemiologyPublic HealthVaccine SafetyMaternal HealthHealth EconomicsVaccine Efficacy

Publications per year

2014–2024

Publications

The Potential Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in Elderly People and Clinical Risk Groups in the UK: A Lifetime Multi-Cohort Model

Laure-Anne Van Bellinghen, Genevieve Meier, Ilse Van Vlaenderen · PLoS ONE · 2014 · 67 citations · Full text

Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model

F Christiaan K Dolk, Martin Eichner, R Welte et al. · PharmacoEconomics · 2016 · 41 citations · Full text

Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States

Daniel Molnar, Elizabeth M. La, Frederik Verelst et al. · Infectious Diseases and Therapy · 2024 · 24 citations · Full text

Economic Impact of Introducing the RTS,S Malaria Vaccine: Cost-Effectiveness and Budget Impact Analysis in 41 Countries

Christophe Sauboin, Laure-Anne Van Bellinghen, Nicolas Van de Velde et al. · MDM Policy & Practice · 2019 · 20 citations · Full text

Potential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling study

Christophe Sauboin, Laure-Anne Van Bellinghen, Nicolas Van de Velde et al. · Malaria Journal · 2015 · 16 citations · Full text

1–5 of 8